Previous 10 | Next 10 |
Gainers: vTv Therapeutics (NASDAQ: VTVT ) +57% . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., NanoViricides, Inc., Stocks on the move, , Read more ...
vTv Therapeutics (NASDAQ: VTVT ) +80% on positive TTP399 data . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., Edgewell Personal Care Company, Stocks on the move, Read more ...
Gainers: Armata Pharmaceuticals (NYSEMKT: ARMP ) +104% . More news on: Armata Pharmaceuticals, Inc., NantHealth, Inc., Delphi Technologies PLC, Stocks on the move, , Read more ...
RTI Surgical Holdings (NASDAQ: RTIX ) +105% on sale of OEM business . More news on: RTI Surgical Holdings, Inc., TransEnterix, Inc., XBiotech Inc., Stocks on the move, , Read more ...
Thinly traded nano cap Mereo BioPharma Group plc (NASDAQ: MREO ) is up 19% premarket on modest volume in reaction to additional data from a Phase 2b clinical trial, ASTEROID , evaluating setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta , also known ...
Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Reaching Statistical Significance in High Dose Cohort Statistically Significant Increase in Trabec...
Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP ) +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Mereo BioPharma Group ( MREO +27.1% ) is up more than double normal volume, albeit on turnover of only 465K shares, on the heels of its out-licensing agreement with Oncologie for exclusive global rights to ovarian cancer candidate navicixizumab, one of two assets M...
Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...
Oncologie receives exclusive global license to develop and commercialize navicixizumab LONDON, and REDWOOD CITY, Calif., and BOSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," and Oncologie, Inc. (“Oncologieȁ...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
Mereo BioPharma Group Website:
2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...
2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...